Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis.
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
[Immunodepressive therapy in neurology].
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.
Multiple sclerosis disease-modifying therapy prescribing patterns in ontario.
Symptom overlap in anxiety and multiple sclerosis.
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.
Differential diagnosis for cervical spondylotic myelopathy: literature review.
Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects.
[Multiple sclerosis: new approaches to comprehensive treatment and rehabilitation using the method of reflexology].
Transcriptional enhancers: from properties to genome-wide predictions.
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis.
Individual variability in speed of information processing: An index of cognitive impairment in multiple sclerosis.
Mortality statistics for multiple sclerosis and amyotrophic lateral sclerosis in sweden.
Month of Birth Does Not Seem to Interfere with the Development of Multiple Sclerosis Later in Life in Brazilian Patients.
The effect of supported standing in adults with upper motor neurone disorders: a systematic review.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR

Pages